Caris
Caris Life Sciences, Ontada Ink Deal to Integrate Genomic, Clinical Cancer Data
The firms will combine Caris' multimodal genomic data with Ontada's community oncology-based real-world data to support cancer drug development.
Caris Life Sciences Expands Access to Urologic Cancer Tests Through Deal With Lumea
The firms agreed to make Caris' whole-exome and whole-transcriptome sequencing tests available through Lumea's BxLink digital pathology software.
Caris Life Sciences CDx Assay Nabs FDA Approval
The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.
Caris Life Sciences, ECOG-ACRIN to Analyze Breast Tumor Samples From Landmark TAILORx Study
Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to FGFR-directed therapy.